A majority with overweight/obesity discontinue within a year, but the rate is higher among those without type 2 diabetes.

A large cohort study examining more than 125,000 adults in the U.S. found that the majority of patients discontinue GLP-1 RA therapy within the first year, with those without Type 2 diabetes showing ...

Taking a compounded GLP-1 medication isn’t the same thing as your pharmacy filling a cheaper, generic version of the drug ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. The age of type 2 ...

SGLT2 inhibitors confer greater risk reductions for major adverse cardiovascular events in older adults with type 2 diabetes ...

Scouted selects products independently. If you purchase something from our posts, we may earn a small commission. Unless you ...

Snack foods and sweet treats have seen a decline in purchases, as people reach for more nutrient-dense options.

Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the short term.

Alexandra Sowa's new book The Ozempic Revolution is intended to be the "first comprehensive user guide" to GLP-1 drugs like ...

Tricia Rodriguez, Truveta senior applied research scientist & lead study author, explains the study findings concerning why ...

Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform consumers.